Compare Mesoblast Limited (MESO) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Quanta Services Inc — how do they compare? Mesoblast Limited trades at $17.03 (market cap $2.21B), while Quanta Services Inc trades at $695.22 (market cap $100.82B). The key difference: Quanta Services Inc is far larger — about 45.6× Mesoblast Limited's market cap, and Quanta Services Inc pays a 0.07% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| MESO | PWR | |
|---|---|---|
Market Cap | $2.21B | $100.82B |
Sector | Technology | Industrials |
52-Week High | $20.96 | $785.24 |
52-Week Low | $12.88 | $372.50 |
Enterprise Value | $2.21B | $106.91B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PWR trades at $660.86, down 1.64% over 24 hours, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.24 versus $3.31 expected, and raised its full-year 2026 outlook. Revenue growth is robust, reaching $28.48B in 2025, though valuation ratios like a P/E of 76.73 appear elevated. Analyst sentiment is overwhelmingly positive, with 26 buy ratings and a consensus price target of $809.75.
The outlook for PWR is bullish, driven by record backlog and infrastructure demand, but high valuation and negative net cash flow pose risks. Investors face a trade-off between strong growth prospects and premium pricing, with execution on raised guidance being critical for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
